Advanced Breast Cancer

Ribociclib Improves PFS in Treatment-naïve Patients With Advanced Breast Cancer

Ribociclib Improves PFS in Treatment-naïve Patients With Advanced Breast Cancer

By

Adding ribociclib to letrozole significantly prolonged progression-free survival compared with letrozole alone in postmenopausal women.

Palbociclib Active in Patients With HR+/HER2- Early-stage Breast Cancer

Palbociclib Active in Patients With HR+/HER2- Early-stage Breast Cancer

By

Short-term pre-operative treatment with palbociclib significantly reduced Ki67 in treatment-naïve patients with early-stage breast cancer.

Ado-trastuzumab Emtansine Evaluated With Docetaxel, Pertuzumab for Breast Cancer

Ado-trastuzumab Emtansine Evaluated With Docetaxel, Pertuzumab for Breast Cancer

By

Ado-trastuzumab emtansine in combination with docetaxel with or without pertuzumab appeared efficacious in breast cancer.

Early Use of Supportive Medications Not Associated With End of Life Care

Early Use of Supportive Medications Not Associated With End of Life Care

By

No association between early use of any supportive medications and end-of-life care among Medicare beneficiaries with advanced breast cancer.

Nab-paclitaxel Benefits Patients With Early Breast Cancer

Nab-paclitaxel Benefits Patients With Early Breast Cancer

By

Patients with early breast cancer experienced a pathologic complete response rate with nab-paclitaxel compared with paclitaxel.

ASCO Issues New Guidelines for Early Breast Cancer Biomarkers

ASCO Issues New Guidelines for Early Breast Cancer Biomarkers

By

An expert ASCO panel identified 9 biomarker tests that may help guide decisions on adjuvant systemic therapy for certain patients with breast cancer.

Abiraterone Acetate Plus Prednisone Beneficial for Some With AR-positive, Triple-negative Breast Cancer

Abiraterone Acetate Plus Prednisone Beneficial for Some With AR-positive, Triple-negative Breast Cancer

By

Treatment with abiraterone acetate plus prednisone was beneficial for some patients with molecular apocrine breast cancer.

FDA Approves Palbociclib for HR+, HER2- Advanced Breast Cancer

FDA Approves Palbociclib for HR+, HER2- Advanced Breast Cancer

By

The FDA approved palbociclib (Ibrance) in combination with fulvestrant for the treatment of patients with breast cancer.

Managing Symptoms Is Key for Patients With Metastatic Cancer Who Continue to Work

Managing Symptoms Is Key for Patients With Metastatic Cancer Who Continue to Work

By

Patients with metastatic cancer who continue to work may need the income or access to health insurance or simply have the desire to work, yet they face a number of hurdles.

FDA 2015 Drug Approvals Encompass Wide Range of Cancer Types

FDA 2015 Drug Approvals Encompass Wide Range of Cancer Types

By

The year 2015 brought treatment advances for patients with myriad cancer types, as reflected in U.S. Food and Drug administration approvals.

Recent Clinical Findings for Targeting CDK 4/6 in Breast Cancer

Recent Clinical Findings for Targeting CDK 4/6 in Breast Cancer

By

Dr Finn reviewed recent clinical study findings for palbociclib, a first-in-class CDK 4/6-specific inhibitor, abemaciclib, and ribociclib.

Declines in Top1-positive Circulating Tumor Cells Associated With Prolonged Survival After Etirinotecan Pegol

Declines in Top1-positive Circulating Tumor Cells Associated With Prolonged Survival After Etirinotecan Pegol

By

Declines in topoisomerase-I (Top1)-positive circulating tumor cells (CTCs) might be a biomarker of prolonged survival in advanced breast cancer.

Blood Test Aids in Identifying Treatment Resistance in Metastatic Breast Cancer

Blood Test Aids in Identifying Treatment Resistance in Metastatic Breast Cancer

By

A new sensitized blood test can help clinicians discover when breast cancers become resistant to standard hormone therapy.

Low-dose Estradiol Effective in Certain Patients With Advanced Breast Cancer

Low-dose Estradiol Effective in Certain Patients With Advanced Breast Cancer

By

Low-dose estradiol is an effective and well tolerated endocrine option in postmenopausal women with advanced breast cancer.

Everolimus Efficacy Independent of Genetic Alterations in EGFR2-negative Breast Cancer

Everolimus Efficacy Independent of Genetic Alterations in EGFR2-negative Breast Cancer

By

An exploratory analysis revealed that the efficacy of everolimus was independent of the most commonly altered genes in breast cancer.

American Cancer Society Updates Breast Cancer Screening Guidelines

American Cancer Society Updates Breast Cancer Screening Guidelines

By

For the first time in a decade, the American Cancer Society has updated its breast screening guidelines.

Etirinotecan Pegol Fails to Improve Survival in Heavily Pre-treated Breast Cancer

Etirinotecan Pegol Fails to Improve Survival in Heavily Pre-treated Breast Cancer

By

Etirinotecan pegol did not significantly improve overall survival in patients with heavily pre-treated advanced breast cancer.

Women in Certain Racial Groups At Higher Risk for Advanced Breast Cancer

Women in Certain Racial Groups At Higher Risk for Advanced Breast Cancer

Women in certain racial/ethnic groups are more likely to be diagnosed with more advanced breast cancer.

ANXA1 Identified as Potential Predictor of Trastuzumab Resistance

ANXA1 Identified as Potential Predictor of Trastuzumab Resistance

By

High tumor expression of ANXA1 could be predictive of trastuzumab resistance in patients with HER-2 positive breast cancer.

Women With Mucinous, Tubular/Cribriform Breast Cancer Fare Better Than Other Histotypes

Women With Mucinous, Tubular/Cribriform Breast Cancer Fare Better Than Other Histotypes

By

Women with mucinous or tubular/cribriform breast cancer had better outcomes than those with other histotypes.

First-Line Fulvestrant May Prolong Survival in Advanced Breast Cancer

First-Line Fulvestrant May Prolong Survival in Advanced Breast Cancer

By

Fulvestrant 500 mg may extend overall survival compared with anastrozole 1 mg as first-line endocrine therapy for advanced breast cancer.

Immunotherapies Shine at ASCO Annual Meeting

Immunotherapies Shine at ASCO Annual Meeting

By

FDA-approved immunotherapies are showing efficacy in different cancer types and combination therapies with new biologics are displaying increased efficacy.

For Breast Cancer, Docetaxel Improves Progression-Free Survival

For Breast Cancer, Docetaxel Improves Progression-Free Survival

By

Docetaxel/capecitabine regimen for breast cancer followed by capecitabine maintenance led to longer progression-free survival.

Certain Taxane Schedules May Improve Outcomes in Breast Cancer

Certain Taxane Schedules May Improve Outcomes in Breast Cancer

By

Weekly paclitaxel and every-3-week docetaxel regimens improved clinical outcomes in women with breast cancer.

Adding Everolimus May Improve Progression-Free Survival in Advanced Breast Cancer

Adding Everolimus May Improve Progression-Free Survival in Advanced Breast Cancer

By

Addition of everolimus notably prolonged progression-free survival in the HR-negative, HER2-positive breast cancer population.

Similar Patient-Reported Outcomes with Exemestane, Tamoxifen in Breast Cancer

Similar Patient-Reported Outcomes with Exemestane, Tamoxifen in Breast Cancer

By

No strong indication to favor either exemestane or tamoxifen for treatment of premenopausal women with early breast cancer.

Prenatal DDT Exposure Linked with Higher Breast Cancer Risk

Prenatal DDT Exposure Linked with Higher Breast Cancer Risk

Women exposed to the chemical in utero may be more likely to develop breast cancer.

Higher Breast Cancer Risk in Obese, Postmenopausal Women

Higher Breast Cancer Risk in Obese, Postmenopausal Women

Risk for breast cancer among obese women may be up to 58 percent higher than for normal-weight postmenopausal women.

Once-Weekly Paclitaxel Remains Preferred for Advanced Breast Cancer

Once-Weekly Paclitaxel Remains Preferred for Advanced Breast Cancer

By

Paclitaxel once per week remains the preferred palliative chemotherapy in patients with chemotherapy-naive advanced breast cancer.

Study Detects Novel Genetic Markers of Breast Cancer Survival

Study Detects Novel Genetic Markers of Breast Cancer Survival

By

Researchers have detected two new genetic markers of breast cancer survival.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs